Sean Cassidy
Director of Finance/CFO presso Arvinas Operations, Inc.
Patrimonio netto: 8 M $ in data 29/02/2024
Profilo
Attualmente, Sean A. Cassidy è direttore finanziario di Arvinas, Inc., direttore finanziario di Arvinas Operations, Inc. (una consociata di Arvinas, Inc.) e Tesoriere di The Friends of Yale New Haven Children's Hospital. In passato il signor Cassidy ha ricoperto la posizione di direttore finanziario e vicepresidente dell'amministrazione presso Renetx Bio, Inc., direttore finanziario e vicepresidente per CuraGen Corp., direttore e controllore presso Deloitte & Touche LLP e direttore e controllore presso 454 Life Sciences Corp. Ha ricevuto un MBA e una laurea presso l'Università del Connecticut.
Partecipazioni note in società pubbliche
Società | Data | Numero di azioni | Valorizzazione | Data di valutazione |
---|---|---|---|---|
ARVINAS, INC.
0.27% | 23/02/2024 | 181 916 ( 0.27% ) | 8 M $ | 29/02/2024 |
Posizioni attive di Sean Cassidy
Società | Posizione | Inizio |
---|---|---|
Arvinas Operations, Inc.
Arvinas Operations, Inc. BiotechnologyHealth Technology Arvinas Operations, Inc. develops novel therapeutics for the treatment of cancer, pro-inflammatory, autoimmune and rare diseases. It offers proteolysis-targeting chimera PROTAC-based drugs that induce protein degradation to target and eliminate disease-causing proteins from the body. The company was founded by Craig M. Crews in July 2013 and is headquartered in New Haven, CT. | Director of Finance/CFO | - |
The Friends of Yale New Haven Children's Hospital | Treasurer | - |
Precedenti posizioni note di Sean Cassidy
Società | Posizione | Fine |
---|---|---|
ARVINAS, INC. | Director of Finance/CFO | 29/02/2024 |
Renetx Bio, Inc.
Renetx Bio, Inc. BiotechnologyHealth Technology Renetx Bio, Inc. operates as a biotechnology company that develops disease modifying therapeutics. It offers Nogo Receptor and Cellular Prion Protein technology. The company was founded by Sylvia McBrinn and Stephen Strittmatter in 2009 and is headquartered in New Haven, CT. | Director of Finance/CFO | 01/06/2013 |
CuraGen Corp.
CuraGen Corp. Pharmaceuticals: MajorHealth Technology CuraGen Corp. develops protein, antibody and small molecule pharmaceutical products. The firm focuses on the development of CR011-vcMMAE, a Phase II clinical trial drug for the treatment of patients with metastatic melanoma and breast cancer. The company was founded in 1991 and is headquartered in Branford, CT. | Director of Finance/CFO | 01/10/2009 |
454 Life Sciences Corp.
454 Life Sciences Corp. Medical/Nursing ServicesHealth Services 454 Life Sciences Corp. engages in the provision of medical testing services to determine the nucleotide sequence of whole genomes. The company was founded by Jonathan M. Rothberg in 2000 and is headquartered in Branford, CT. | Director/Board Member | 01/12/2008 |
Deloitte & Touche LLP
Deloitte & Touche LLP Miscellaneous Commercial ServicesCommercial Services Deloitte & Touche LLP engages in the provision of audit, advisory, financial advisory, tax, and consulting services. The company was founded on March 7, 1995 and is headquartered in New York, NY. | Director/Board Member | 01/05/2001 |
Formazione di Sean Cassidy
University of Connecticut | Masters Business Admin |
Esperienze
Posizioni ricoperte
Attive
Inattive
Società quotate in Borsa
Aziende private
Relazioni
Relazioni di 1° grado
Aziende connesse in 1º grado
Uomo
Donna
Amministratori
Dirigenti
Società collegate
Società quotate in Borsa | 1 |
---|---|
ARVINAS, INC. | Health Technology |
Aziende private | 6 |
---|---|
CuraGen Corp.
CuraGen Corp. Pharmaceuticals: MajorHealth Technology CuraGen Corp. develops protein, antibody and small molecule pharmaceutical products. The firm focuses on the development of CR011-vcMMAE, a Phase II clinical trial drug for the treatment of patients with metastatic melanoma and breast cancer. The company was founded in 1991 and is headquartered in Branford, CT. | Health Technology |
Renetx Bio, Inc.
Renetx Bio, Inc. BiotechnologyHealth Technology Renetx Bio, Inc. operates as a biotechnology company that develops disease modifying therapeutics. It offers Nogo Receptor and Cellular Prion Protein technology. The company was founded by Sylvia McBrinn and Stephen Strittmatter in 2009 and is headquartered in New Haven, CT. | Health Technology |
Arvinas Operations, Inc.
Arvinas Operations, Inc. BiotechnologyHealth Technology Arvinas Operations, Inc. develops novel therapeutics for the treatment of cancer, pro-inflammatory, autoimmune and rare diseases. It offers proteolysis-targeting chimera PROTAC-based drugs that induce protein degradation to target and eliminate disease-causing proteins from the body. The company was founded by Craig M. Crews in July 2013 and is headquartered in New Haven, CT. | Health Technology |
Deloitte & Touche LLP
Deloitte & Touche LLP Miscellaneous Commercial ServicesCommercial Services Deloitte & Touche LLP engages in the provision of audit, advisory, financial advisory, tax, and consulting services. The company was founded on March 7, 1995 and is headquartered in New York, NY. | Commercial Services |
454 Life Sciences Corp.
454 Life Sciences Corp. Medical/Nursing ServicesHealth Services 454 Life Sciences Corp. engages in the provision of medical testing services to determine the nucleotide sequence of whole genomes. The company was founded by Jonathan M. Rothberg in 2000 and is headquartered in Branford, CT. | Health Services |
The Friends of Yale New Haven Children's Hospital |